Purchase this article with an account.
A.F. Bordon, J.F. Kuczmainski, A. Gelmini, Jr., M. Schirmer, L.S. G. Lima, A. Vargas, L. Okimoto; Photocoagulation versus 8 mg Intravitreous Trimcinolone Acetate (TAAC) for Diabetic Clinical Significant Macular Edema (CSME): A Prospective Study . Invest. Ophthalmol. Vis. Sci. 2006;47(13):3844.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
to compare the results between photocoagulation and 8 mg TAAC in patients with CSME
patients with the diagnosis of CSME were randomly assigned to receive either intravitreous 8 mg/0.2 ml of TAAC or standard laser photocoagulation. Complete ophthalmological examination was performed before the treatment, including best corrected visual acuity using the ETDRS chart, fluorescein angiogram and fundus biomicroscopy. Follow up visits were done on the first day, first month and every three months until 12 months. Treatment was repeated every 3 months, if necessary
Thirty–three eyes of 26 patients were enrolled. Median age was 58.1 years (range, 43–71 years). Nineteen were women and 7 were men. Photocoagulation was performed in 18 eyes, whereas TAAC was carried out in 15 eyes. The mean number of ETDRS letters read before treatment was 35.4 in the photocoagulation group and 28.3 in the TAAC group. After 12 months, the mean was 32.4 and 36.3 in the photocoagulation and in the TAAC group, respectively. Re–treatments were performed in the laser group and TAAC group as follows: at 3 months: 72.1% and 53.3%, respectively; at 6 months: 61.1% and 61.5%, respectively; at 9 months: 27.8% and 61.5%, respectively; and at 12 months: 38.9% and 69.3%, respectively
At 12 months, the TAAC group gained more ETDRS letters compared to the photocoagulation group. However, TAAC group needed more re–treatments compared to photocoagulation group
This PDF is available to Subscribers Only